Cell Signaling Technology Logo - Extra Large

Phospho-FLT3 (Tyr591) Antibody (Alexa Fluor® 488 Conjugate) #3459

Inquiry Info. # 3459

Please see our recommended alternatives.

    Product Specifications

    REACTIVITY
    SENSITIVITY Endogenous
    MW (kDa)
    SOURCE Rabbit

    Product Information

    Product Description

    This Cell Signaling Technology Antibody was conjugated to Alexa Fluor®488 fluorescent dye and tested in-house for direct flow cytometric analysis of human cells. The unconjugated antibody #3461 reacts with human and mouse Phospho-FLT3 (Tyr591). CST expects that Phospho-FLT3 (Tyr591) Antibody (Alexa Fluor® 488 Conjugate) will also recognize Phospho-FLT3 (Tyr591) in these species.

    Storage

    Supplied in PBS (pH 7.2), less than 0.1% sodium azide and 2 mg/ml BSA. Store at 4°C. Do not aliquot the antibody. Protect from light. Do not freeze.

    Specificity / Sensitivity

    Phospho-FLT3 (Tyr591) Antibody (Alexa Fluor® 488 Conjugate) detects endogenous FLT3 only when phosphorylated at tyrosine 591. This antibody conjugate does not cross-react with other FLT family members. This antibody conjugate may cross-react with some tyrosine phosphorylated proteins. (US Patent No. 7,183,385 and foreign equivalents assigned to Cell Signaling Technology, Inc.)

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr591 of human FLT3. Antibodies are purified by protein A and peptide affinity chromatography.The antibody was conjugated to Alexa Fluor®488 under optimal conditions with an F/P ratio of 2-5.

    Background

    FMS-related tyrosine kinase 3 (FLT3, also called FLK2) is a member of the Type III receptor tyrosine kinase family, which includes c-Kit, PDGFR, and M-CSF receptors. FLT3 is expressed on early hematopoietic progenitor cells and supports growth and differentiation within the hematopoietic system (1,2). FLT3 is activated after binding with its ligand FL, which results in a cascade of tyrosine autophosphorylation and tyrosine phosphorylation of downstream substrates (3). The p85 subunit of PI3 kinase, SHP2, GRB2, and Shc have all been reported to associate with FLT3 after FL stimulation (4-6). Tyr589/591 is located in the juxtamembrane region of FLT3 and may play an important role in regulation of FLT3 tyrosine kinase activity. Somatic mutations of FLT3 consisting of internal tandem duplications (ITDs) occur in 20% of patients with acute myeloid leukemia (7).

    Alternate Names

    CD135; CD135 antigen; fetal liver kinase 2; Fetal liver kinase-2; FL cytokine receptor; FLK-2; FLK2; FLT-3; FLT3; FLT3 receptor tyrosine kinase; fms related receptor tyrosine kinase 3; fms related tyrosine kinase 3; Fms-like tyrosine kinase 3; fms-related tyrosine kinase 3; growth factor receptor tyrosine kinase type III; Receptor-type tyrosine-protein kinase FLT3; Stem cell tyrosine kinase 1; STK-1; STK1; Tyrosine-protein kinase receptor FLT3

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or [email protected].
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.